INTRODUCTION
In 2010, the American Heart Rhythm Society (AHRS) released its consensus statement [1 && ] on the management of Cardiovascular Implantable Electronic Devices (CIEDs) for patients who were requesting withdrawal of the device because of the burdens of the device and/or because they were nearing the end of their life. Concurrently, the European Heart Rhythm Association (EHRA) released its consensus statement [2] . Both statements reviewed the ethical and legal concerns with device deactivation, provided a framework for analyzing the concerns and suggested a practical approach for the deactivation process. This article will briefly review the two consensus statements, some of the subsequent research and suggest a preventive ethical approach to deactivation.
CONSENSUS STATEMENTS
The AHRS created its consensus statement to dispel confusion about the acceptability of device deactivation. AHRS states that patients do not have to be terminal to have a device deactivated, however, it is more common for this request to be made toward the end-of-life (EOL). The AHRS firmly states that 'carrying out a request to withdraw life-sustaining treatment is neither physician-assisted suicide (PAS) nor euthanasia' and 'the right to refuse or request the withdrawal of a treatment is a personal right of the patient and does not depend on the characteristics of the particular treatment'. Therefore, no treatment has 'unique, ethical or legal status' [1 && ]. The AHRS presents deactivation as removal of unwanted therapy even after it has begun. Rady et al.
[3 necessity for physician intervention to remove the device's activity as either PAS or euthanasia. AHRS explicitly describes PAS and euthanasia as the addition of further modalities to affect the patient's death, whereas deactivation is removal. Intention of the physician is most critical to determining acceptability of the practice.
Much of the AHRS statement is devoted to a careful description of the necessary steps for ethical deactivation. Crucial to initiating this process is conversation with the patient and/or appropriate family members as to what deactivation entails, the uncertainties of deactivation and the safeguards to the process, such as possible psychiatric evaluation and palliative care consultation. Magyar-Russell et al. [4] suggest the rate of depression in defibrillator patients is about 20%, thus psychiatric consultation may be appropriate. Of course, advance directives, if available, should be reviewed for deactivation statements.
AHRS supports care provider conscientious objection but recommends they assist in the orderly transfer of care to a willing provider.
Considerations for deactivation in the pediatric population are also presented. The number of devices in children is increasing [5] as the effectiveness of the devices continues to be demonstrated, and as medicine develops the genetic analysis tools to determine which children are at risk. Parents will of course be deeply involved with the decisionmaking. Age appropriate discussions with children are encouraged and cues for discussion content should be sought from parents.
The EHRA statement is similar to the AHRS statement. It states that advance directives are not fully accepted in every nation and that pacemaker deactivation is prohibited in some nations. Similarly to the AHRS, there are sections devoted to the pediatric population, to the process involved in deactivation and to conscientious objection.
Both statements encourage conversation about deactivation at the time of implantation.
LITERATURE REVIEW OF END-OF-LIFE CONSIDERATIONS
Timely discussion about deactivation is one of the major recurring themes in recent research. Russo [6] reviewed 14 articles that were published in the 10 years prior to the AHRS statement. He found significant physician reluctance to talk about deactivation, which meant patients were unaware of the deactivation option, which then led to the trauma of patients being unnecessarily shocked as they were dying.
Additional surveys have demonstrated the lack of uniformity of information sharing about deactivation. Kramer et al. [7] sought the views of lay members of the Hypertrophic Cardiomyopathy Association on deactivating defibrillators and pacemakers. Religious, ethical and legal uncertainties were expressed by many of the respondents. Of those, who had completed advance directives, only 8% mentioned their device.
Further, Kirkpatrick et al. [8] performed a telephone survey of 278 patients with defibrillators. About half had completed advance directives but only 1% had made mention of their device. Remarkably, 86% stated that they had not thought about what to do with the device if they were to have a serious, nonrecoverable illness.
Dodson et al. [9] presented five EOL scenarios to 95 patients with defibrillators, seeking their interest in device deactivation. Seventy-one percent of the 95 patients were interested in deactivation in at least one of the scenarios.
These studies conclude that most patients are interested in talking about deactivation, that patients have misunderstandings about the ethical and legal acceptability of deactivation, and that physicians should take the initiative in starting the deactivation option conversation.
Strachan et al. [10] interviewed 24 patients, who chose to have a defibrillator and six who refused implantation. When asked to consider EOL concerns, the patients believed that the conversation should occur sooner rather than later because 'EOL planning should not begin at the EOL'. Strachan et al. highlight the paradoxical nature of death and defibrillators. When the device is implanted, the idea of sudden cardiac death (SCD) avoidance is appealing, however as other illnesses with their attendant limitations impact the patient's perceived quality of life, the patient may begin to view SCD as a welcome alternative to slow decline. This is only possible if the defibrillator is deactivated. Of course,
KEY POINTS
Mention of the deactivation option should be made at the time of the implantation discussion.
Encourage patients to fill out advance directives, specifically addressing their intracardiac device.
Awareness of the process of deactivation will ease concerns among all staff when a request for deactivation is made.
Institutions should create policies describing an ethical deactivation process.
it must be explained that device deactivation does not guarantee SCD.
Raphael et al. [11] interviewed a small number of patients asking them to remember the informed consent conversation before implantation, particularly whether or not they were advised of the possibility of deactivation and when the patients believed the conversation about deactivation should be had, if not done during the preimplantation phase. Patient responses suggest there was inadequate understanding of deactivation, with only 38% realizing that this was an option.
Kapa et al. [12 & ] asked legal and medical professionals as well as patients about their beliefs regarding deactivation of defibrillators and pacemakers at the EOL. Interestingly, approval of deactivation was device specific for patients and medical professionals, whereas the legal professionals viewed all of the devices as virtually identical, thus their responses were identical across device type. The greatest disagreement about appropriate deactivation was for pacemaker-dependent patients. The AHRS statement does not distinguish amongst devices.
Matlock et al. [13] queried both physicians and patients about decision-making for defibrillator therapy. Many responding cardiologists used current guidelines as the basis for device recommendation, with little emphasis on patient goals and values as part of the decision-making process. There was great variability about mentioning deactivation in the implantation discussion. Patients who refused implantation believed that the defibrillator would merely prolong a dying process.
Caverly et al. [14] also found that more than half of the physicians focused on guidelines for implantation rather than patient preferences. This guideline-based approach creates an assumption that 'of course' a battery or faulty lead would be replaced, thus limiting the perceived need for deactivation conversations.
Kramer et al. [15] suggest that the automatic replacement of batteries described by Caverly is all too common. Physicians were encouraged to view the battery change conversation as an opportunity to remind patients of the deactivation option and to promote the completion of advance directives. Increased communication among all the physicians involved in the patient's care as well as a more robust discussion of options with the patient, starting with the preimplantation informed consent process was also encouraged.
DEACTIVATION SURVEYS
Fromme et al. [16 & ] surveyed Oregon hospices and found that most healthcare providers had encountered problems caring for patients with CIEDs, particularly unwarranted shocks leading to distraught family members and hospice staff. Less than half of the respondents had a policy about deactivation. Fromme et al. [16 & ] provides a sample policy that contains many of the AHRS suggestions.
Lakshmanadoss et al. [17] contrasted an academic hospice with a community hospice and found greater deactivation in the academic hospice. Deactivation discussion was encouraged at the time the patient opts for hospice so that the shocks can be avoided.
DEACTIVATION DISCUSSION
The consensus from these surveys is that patients ought to be told at the preimplantation discussion that the device can be deactivated when there is a change in the patient's perception of the benefits and burdens of the device. Physicians express anxiety about this conversation as a discussion about deactivation before implantation appears contradictory. Imagined patient confusion and apprehension may be a disincentive to the conversation. However, imagined patient harm and family ire at unnecessary shocks at the EOL is a helpful counter. Deactivation information can be reasonably covered in one sentence: 'At some future date, if you decide you no longer want the device, it can easily be disabled'. This single sentence conveys the idea that the device is for the benefit of the patient, and that the patient has control over its use. If patients express interest in the option, the physician can provide more information. If patients appear satisfied, the physician can cover other aspects of implantation. The reluctance to have this conversation makes it easy to put off which only makes it more difficult to initiate the conversation at a later time [18] .
At the time of battery change, at the time of a device recall, at the time of other life limiting diagnoses, and at the time of hospice entrance, the reminder may become of more interest to the patient. As the patient more seriously considers the deactivation, the complexities of the process should be explained. The American Heart Association [19] [22] all suggest discussion points to be covered. Physician anxiety about these discussions can be ameliorated by inclusion of palliative care specialists who have skills for initiating and continuing difficult conversations. Observation of the palliative care specialists may also help physicians develop their own personal approach.
DO-NOT-RESUSCITATE (DNR) ORDERS
Patients are able to exert increased control over the time and manner of their deaths than in the past. Some find this inappropriate relative to their religious or spiritual understanding of death, in which case deactivation may not be an EOL choice. For others who wish to not prolong death, device deactivation may be appealing at the EOL.
Deactivation and DNR orders are related but not inextricably so. If a patient is near EOL and a deactivation decision is made, a DNR order would be reasonable. For a patient, who has just had the device implanted, CPR hopefully will not be needed, but would likely be appreciated.
There are some patients who request deactivation without a terminal illness; for them the defibrillator shocks are so overwhelming that they are willing to accept the risk of SCD. These patients do want to live -without the defibrillator -thus a DNR order would be inappropriate.
When death is anticipated, a patient might request a DNR order but also understand that a defibrillator shock provides the best chance of living a few more days and therefore ask that the defibrillator remain active. This last scenario is rare but understandable.
PACEMAKERS
The recent surveys include more objections to pacemaker deactivation than to defibrillator deactivation. From the standpoint of the patient's right to refuse therapy, the type of device is irrelevant: unwanted therapies are unwanted therapies. However, because there appear to be few burdens to pacemakers, some practitioners understandably have greater difficulty granting the request.
The compact nature of the device (thus no esthetic concerns), its nonpainful functioning (in reality, no awareness of functioning), long life batteries and minimal physician management appear to create a 'no harm' therapeutic maneuver [23] . Physicians express concern that pacemaker deactivation will cause an immediate death in those who are completely pacemaker-dependent and other physicians express concern that deactivation in a partially dependent patient will lead to a more uncomfortable death with increasing cardiac symptoms. The first argument is a proximate cause argument that overlooks the overall decline the patient is experiencing as well as the established right of a patient to refuse therapies.
In the second case (worsening of cardiac symptoms), there is a distinct role for palliative care providers to help with symptom control. There must be conversation about the anticipated outcome of pacemaker deactivation with the patient and family. Both of these concerns (immediate death or increased symptoms) ought to be described to the patient so as to create a thoughtful, informed choice. AHRS does not make any distinction about the type of intracardiac device and fully supports an informed patient choice. One case review [24 & ] described a patient's request for pacemaker deactivation and the concerns of the healthcare providers. When the pacemaker was deactivated there was minimal discomfort and the more peaceful death sought by the patient was achieved.
We do not have a large repository of pacemaker deactivation stories but it would be of great benefit. Descriptions of the death trajectory after deactivation in patients who were and were not completely pacemaker-dependent might help focus conversation toward appropriate symptom management.
PREVENTIVE ETHICS
Clinicians ought to reflect on their willingness to deactivate devices, remembering that AHRS supports appropriate deactivation as well as the conscientious objection stance. Those clinicians who are willing to disable need to determine under what circumstances they would agree to the patient request. If the physician is willing to disable, selfeducation before patient education must occur. In this regard talking with device manufacturer representatives about the details of disabling will minimize confusion about the process. Finally, physicians should participate in policy creation so that ethical deactivation is achieved. Understanding nurses' [25] and device manufacturer representatives' [26] perspectives will help create a policy that is more acceptable to these involved parties.
It is clear that the patients do need to be informed of the stance of the physician about device disabling. Early conversation enhances patient understanding of options available to them as their health changes and as their goals and values change. It may seem ironic to talk about deactivation when the device is being placed, but a simple sentence about disabling should minimize misunderstandings.
If patients have several physicians involved in their care, it becomes easy for each physician to assume that another physician will have the conversation about deactivation. If in the chain of physicians, any one physician is uncomfortable with broaching deactivation or objects to disabling, there may be no conversation. This prevents a fully informed patient decision.
Preimplantation informed consent discussions should also encourage advance directive completion. If the patient designates an agent, then it would be worthwhile for the patient to have a specific discussion with the agent about the device. It is imperative to document patient goals and values relative to their respective health concerns and these devices.
CONCLUSION
Intracardiac device guidelines have primarily focused on appropriate use. It is equally important to have high-quality communication about deactivation. Guidelines for this conversation and for practice implementation are finally being promulgated to the healthcare and lay communities.
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